Diğer

Ondansetron is a selective serotonin 5-HT3 receptor antagonist originally developed and FDA-approved for the prevention of nausea and vomiting caused by chemotherapy, radiation therapy, and surgery. It works by blocking serotonin signaling in both the gut and the brain's chemoreceptor trigger zone, making it one of the most effective and widely prescribed anti-emetics available. In the performance-enhancement and peptide community, ondansetron has become an essential support compound for managing nausea caused by a range of commonly used agents. GLP-1 receptor agonists like semaglutide and tirzepatide are notorious for dose-dependent nausea, particularly during titration phases, and ondansetron is the go-to solution for keeping users compliant with their protocols. It is similarly relied upon for nausea triggered by HCG, nandrolone (Deca/NPP), pramipexole, and various oral compounds that cause gastric distress. The orally disintegrating tablet (ODT) formulation is especially popular because it dissolves on the tongue in seconds and does not require swallowing a pill while actively nauseated.

Vesilute is a Khavinson bioregulator dipeptide consisting of glutamic acid and aspartic acid (ED), developed at the St. Petersburg Institute of Bioregulation and Gerontology. It is specifically designed to support bladder and urinary tract function, with research indicating potential benefits for prostate health in men. Vesilute may help regulate smooth muscle function, enhance tissue blood flow, and support cellular regeneration in urogenital tissues. It is distinct from Vesugen (KED tripeptide), which targets vascular endothelium.